(Total Views: 565)
Posted On: 10/07/2019 9:07:36 AM
Post# of 30015
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Re: biotechmania #27997
It seems AMBS strategy is anchored around Todos up-listing, and the delay is causing some pain. I think the funds raised through Reg A are mostly going to buy back debt/securities that are not converting at up-list. Since the Reg A filing will go through several iterations, it is a little disappointing that it was priced so low.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)